- Home
- AMBO vs SNSE Comparison
AMBO vs SNSE Comparison
Compare AMBO & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- SNSE
- Stock Information
- Founded
- AMBO 2000
- SNSE 2005
- Country
- AMBO United States
- SNSE United States
- Employees
- AMBO N/A
- SNSE N/A
- Industry
- AMBO Other Consumer Services
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- SNSE Health Care
- Exchange
- AMBO Nasdaq
- SNSE Nasdaq
- Market Cap
- AMBO 8.8M
- SNSE 9.3M
- IPO Year
- AMBO 2010
- SNSE 2021
- Fundamental
- Price
- AMBO $3.19
- SNSE $0.34
- Analyst Decision
- AMBO
- SNSE Strong Buy
- Analyst Count
- AMBO 0
- SNSE 4
- Target Price
- AMBO N/A
- SNSE $4.25
- AVG Volume (30 Days)
- AMBO 27.3K
- SNSE 114.1K
- Earning Date
- AMBO 12-30-2024
- SNSE 05-06-2025
- Dividend Yield
- AMBO N/A
- SNSE N/A
- EPS Growth
- AMBO N/A
- SNSE N/A
- EPS
- AMBO 0.11
- SNSE N/A
- Revenue
- AMBO $9,392,000.00
- SNSE N/A
- Revenue This Year
- AMBO N/A
- SNSE N/A
- Revenue Next Year
- AMBO N/A
- SNSE N/A
- P/E Ratio
- AMBO $28.89
- SNSE N/A
- Revenue Growth
- AMBO 2.50
- SNSE N/A
- 52 Week Low
- AMBO $1.00
- SNSE $0.25
- 52 Week High
- AMBO $5.55
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- AMBO 59.88
- SNSE 40.28
- Support Level
- AMBO $3.02
- SNSE $0.33
- Resistance Level
- AMBO $3.39
- SNSE $0.38
- Average True Range (ATR)
- AMBO 0.32
- SNSE 0.03
- MACD
- AMBO 0.01
- SNSE -0.01
- Stochastic Oscillator
- AMBO 64.37
- SNSE 8.06
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).